Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients
Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients
(Bloomberg) -- About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater access to its human insulin and lower prices, while al...
FDA approves novel gene therapy for rare neurometabolic disorder
FDA approves novel gene therapy for rare neurometabolic disorder
The FDA has approved an adeno-associated virus vector-based gene therapy to treat both adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency.
Pfizer
Pfizer
Pfizer explores sale of hospital drugs unit amid activist investor’s call for accountability: Reuters
Evaxion
Evaxion
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V
Drug R&D
Drug R&D
With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson‘s (J&J) nipocalimab for treating individuals with...
International Congress for Ataxia Research
International Congress for Ataxia Research
Preclinical + International Congress for Ataxia Research
FDA Takes Step Toward Removal of Ineffective Decongestants From the Market
FDA Takes Step Toward Removal of Ineffective Decongestants From the Market
FDA Takes Step Toward Removal of Ineffective Decongestants From the Market
Eisai
Eisai
Eisai lowers Leqembi revenue forecast after rocky entry to market
Mustang Bio’s MB-108
Mustang Bio’s MB-108
Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment
VitalityXtra
VitalityXtra
VitalityXtra may be harmful due to hidden drug ingredient
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand